Vietnam Investment Review on MSN

HKSTP partners with Merck opening innovation centre in Hong Kong

HONG KONG SAR – Media OutReach Newswire – 26 October 2026 – Hong Kong Science and Technology Parks Corporation (HKSTP) and ...
The Manila Times

HKSTP Partners with Leading Science and Technology Company Merck to Open a New Chapter in I&T Collaboration

New Merck Hong Kong Centre to Connect Global Expertise with Local Innovators and Accelerate R&D Commercialisation ...
The Scientist

Positive Melanoma mRNA Vaccine Trial Data Sparks Personalized Medicine Hope

Merck and Moderna’s new personalized cancer vaccine paired with the standard of care reduced the risk of recurrence and death ...
UVA Today

Q&A: Could a new melanoma vaccine change cancer treatment?

The promising new vaccine reduced the risk of melanoma returning by 42%. A UVA Health researcher explains why the results ...
Rutland Herald

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced new two-year follow up results from ...

130% Premium Over Closing Price at $20 per ADS: The Depths of Merck's Acquisition of Silence Therapeutics [M&A Strategy Analysis Report]

Executive SummaryHow to Interpret Two Premiums and Explain the Acquisition Price of a Loss-Making Company (Merck's ...
NewsBytes

Moderna and Merck's vaccine with Keytruda reduces melanoma spread 38%

A personalised cancer vaccine developed by Moderna and Merck shows promise in reducing melanoma metastasis risk by 38% using ...
WSVN 7News

Experimental mRNA vaccine cuts risk that melanoma returns by 42%

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage ...
Investor's Business Daily

How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs

Shares have a perfect IBD Composite Rating of 99. This means the stock ranks in the leading 1% of all stocks when it comes to ...

A personalized cancer vaccine could be available as soon as 2027. Here’s what we know

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising ...

Personalized mRNA melanoma vaccine cuts recurrence risk by 42% in late-stage trial

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were ...